Bone health and therapeutic agents in advanced prostate cancer

Bone health and therapeutic agents in advanced prostate cancer

Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone lo...

Full description

Bibliographic Details
Main Authors:	Maria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renée Bultijnck, Paul Sargos, Piet Ost, Felipe Couñago
Format:	Article
Language:	English
Published:	IMR Press 2022-01-01
Series:	Frontiers in Bioscience-Landmark
Subjects:	bone health prostate cancer skeletal-related events osteoporosis denosumab bisphosphonates
Online Access:	https://www.imrpress.com/journal/FBL/27/1/10.31083/j.fbl2701034

Similar Items

Current treatment of osteoporosis
by: Subramanian Nallasivan
Published: (2019-01-01)

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
by: Christian Meier, et al.
Published: (2017-08-01)

Cancer treatment-induced bone loss
by: Yong Jun Choi
Published: (2024-09-01)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01)

Periapical status in patients affected by osteoporosis: A retrospective clinical study
by: Erika Cadoni, et al.
Published: (2022-10-01)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
by: Mark Clemons, et al.
Published: (2021-10-01)

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study
by: Alexander Stanoyevitch, et al.
Published: (2021-08-01)

Which treatment to prevent an imminent fracture?
by: Iconaru Laura, et al.
Published: (2021-12-01)

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
by: Dávid Száraz, et al.
Published: (2024-12-01)

Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry‐Based Cohort Study
by: Judith Everts‐Graber, et al.
Published: (2022-10-01)

A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years
by: Dora Karimi, et al.
Published: (2024-09-01)

Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications
by: Kaleen N. Hayes, et al.
Published: (2024-03-01)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
by: Tetsuya Kaneko, et al.
Published: (2019-10-01)

Osteogenesis imperfecta as a cause of death
by: Anastasia A. Malygina, et al.
Published: (2018-04-01)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Treatment of primary osteoporosis in men
by: Giusti A, et al.
Published: (2014-12-01)

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma
by: Petra Rugani, et al.
Published: (2016-09-01)

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
by: Peyman Hadji, et al.
Published: (2017-06-01)

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS
by: Francesco Bertoldo, et al.
Published: (2025-02-01)

Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement
by: N. V. Toroptsova
Published: (2018-12-01)

Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis
by: Shivani Sharma, et al.
Published: (2024-08-01)

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
by: Jia Yang, et al.
Published: (2024-09-01)

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study
by: Koki Tsuchiya, et al.
Published: (2021-06-01)

Antiresorptive activity of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis
by: Nadezhda Y. Banshchikova, et al.
Published: (2018-12-01)

OSTEOPOROSIS AND JOINT REPLACEMENT
by: Holzer Gerold, et al.
Published: (2018-08-01)

Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case
by: Dahlia F Davidoff, et al.
Published: (2020-10-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
by: Jean-Jacques Body, et al.
Published: (2018-09-01)

Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
by: Amman Bhasin, et al.
Published: (2025-02-01)

Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study
by: Tzai-Chiu Yu, et al.
Published: (2024-12-01)

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy
by: Enrique Casado, et al.
Published: (2022-01-01)

Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
by: Juan Erviti, et al.
Published: (2017-05-01)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01)

Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool
by: Kamal Kant Sahu, et al.
Published: (2022-11-01)

Bone metastases: Are we failing our patients?
by: B. Tombal, et al.
Published: (2014-05-01)

Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
by: Chiao-Ling Chen, et al.
Published: (2024-12-01)

Use and risk of side effects of antiresorptive medication in people with intellectual disabilities [version 1; peer review: 2 approved]
by: Valeria Frighi, et al.
Published: (2022-12-01)

Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases
by: Hoon-Je Chang, et al.
Published: (2023-02-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort
by: Cristina Mirelli, et al.
Published: (2022-05-01)